Hematological effects of valproate in psychiatric patients: What are the risk factors?

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 282-285

  Vasudev, Kamini ^a   Keown, Patrick ^b   Gibb, Ian ^c   McAllister Williams, Richard Hamish ^d  

^a TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bipolar disorder; Hematological; MCV; Thrombocytopenia; Valproate

Indexed keywords

HEMOGLOBIN; VALPROIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MENTAL PATIENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREND STUDY;

EID: 77952368637     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181db2684     Document Type: Article

References (23)

1. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000;22:62-65.
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder 2002. Am J Psychiatry. 2001;159(4 Suppl):1-50.
3. Goodwin GM, for the consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23:346-388.
4. Baldessarini RJ, Bolzani L, Cruz N, et al. Onset-age of bipolar disorders at six international sites. J Affect Disord. 2010;121:143-146.
5. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.
6. Asnis GM, Friedman TA, Sanderson WC, et al. Suicidal behaviours in adult psychiatric outpatients, I: description and prevalence. Am J Psychiatry. 1993;150:108-112.
7. Vasudev K, Das S, Goswami U, et al. Pharmacokinetics of valproic acid in patients with bipolar disorder. J Psychopharmacol. 2001;15: 187-190.
8. Trannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry. 2001;158: 128-130.
9. De Berardis D, Campanella D, Matera V, et al. Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder. J Clin Psychopharmacol. 2003;23:451-458.
10. Conley EL, Coley KC, Pollock BG, et al. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital. Pharmacotherapy. 2001;21:1325-1330.
11. Delgado MR, Riela AR, Janith Mills PAC. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol. 1994;9:311-314.
12. Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008;49:438-445.
13. Tohen M, Castilla J, Baldessarini RJ, et al. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2228 patients at risk. Am J Psychiatry. 1995;152:413-418.
14. Bowden CL, Calabrese JR, McElroy SL, et al. A randomised, placebo-controlled 12 month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57:481-489.
15. Tohen M, Baker R, Altshuler L, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011-1017. (Pubitemid 34586948)
16. Gomez Bellver MJ, Garcia Sanchez MJ, Alonso Gonzalez AC, et al. Plasma protein binding kinetics of valproic acid over a broad range: therapeutic implications. J Clin Pharm Ther. 1993;18:191-197.
17. Warkentin TE, Sheppard JA, Siqouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;8(9):2937-2941.
18. Kodama Y, Kodama H, Kuranari M, et al. Gender-or age-related binding characteristics of valproic acid to serum proteins in adult patients with epilepsy. Eur J Pharm Biopharm. 2001;52(1):57-63.
19. Pope HG, McElroy SL, Keck PE, et al. Valproate in the treatment of acute mania. Arch Gen Psychiatry. 1991;48:62-68.
20. Bowden CL, Janicak PG, Orsulak P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996;153:765-770.
21. Hirschfeld RMA, Baker JD, Wozniak P, et al. The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J Clin Psychiatry. 2003;64:841-846.
22. Allen MH, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry. 2006;163:272-275.
23. May RB, Sunder TR. Haematologic manifestations of long-term valproate therapy. Epilepsia. 1993;34(6):1098-1101.